CAPRICOR THERAPEUTICS, INC.
CAPRICOR THERAPEUTICS, INC. (CAPR): 4 pipeline candidates · 2 upcoming catalysts · ~28 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
27.8 months
D/E 0.17 · 0% dilution
Lead: Phase 3
4 candidates
2 upcoming, next in ~65d
0 buys · 7 sells (180d)
A transparent, data-derived signal for CAPRICOR THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$105.4M
Quarterly Burn
$29.3M
Runway
27.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| Deramiocel | Phase 3 |
| duchenne muscular dystrophy" | Phase 3 |
| stealthx vaccine | Phase 1 |
| StealthX™ exosome protein-based vaccine (multivalent design) | Phase 1 |
Upcoming Catalysts (2)
Binary FDA approval decision — outcome can sharply revalue the stock.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
179
Total value held
$1.20B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,055,464 | $123.3M |
| suvretta capital management, llc | 3,818,600 | $116.1M |
| blackrock, inc. | 3,421,815 | $104.0M |
| tang capital management llc | 3,399,900 | $103.4M |
| state street corp | 2,181,901 | $66.3M |
| ra capital management, l.p. | 1,507,844 | $45.8M |
| citadel advisors llc | 1,439,832 | $43.8M |
| susquehanna international group, llp | 1,365,075 | $41.5M |
| geode capital management, llc | 1,118,326 | $34.0M |
| diadema partners lp | 1,031,551 | $31.4M |
Showing top 10 of 179 institutional holders of CAPRICOR THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in CAPRICOR THERAPEUTICS, INC.'s pipeline?
CAPRICOR THERAPEUTICS, INC. (CAPR) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CAPRICOR THERAPEUTICS, INC.'s lead drug candidate?
CAPRICOR THERAPEUTICS, INC.'s most advanced tracked candidate is Deramiocel (Phase 3) for Muscular Dystrophies.
What is CAPRICOR THERAPEUTICS, INC.'s next catalyst?
CAPRICOR THERAPEUTICS, INC.'s next tracked catalyst is a PDUFA event — "PDUFA Date: deramiocel" — expected August 22, 2026.
What is CAPRICOR THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CAPRICOR THERAPEUTICS, INC. has approximately 27.8 months of cash runway.
What is CAPRICOR THERAPEUTICS, INC.'s market capitalization?
CAPRICOR THERAPEUTICS, INC.'s market capitalization is approximately $1.6B.
Get the full picture on CAPRICOR THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.